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Background: Dietary sodium restriction is a key management strategy in chronic kidney disease (CKD). Recent
evidence has demonstrated short-term reduction in blood pressure (BP) and proteinuria with sodium restriction,
however the effect on other cardiovascular-related risk factors requires investigation in CKD.
Methods: The LowSALT CKD study involved 20 hypertensive Stage III-IV CKD patients counselled by a dietitian to
consume a low-sodium diet (<100 mmol/day). The study was a randomised crossover trial comparing 2 weeks of
high-sodium (additional 120 mmol sodium tablets) and low-sodium intake (placebo). Measurements were taken
after each crossover arm including BP (peripheral and central), adipokines (inflammation markers and adiponectin),
volume markers (extracellular-to-intracellular [E/I] fluid ratio; N-terminal pro-brain natriuretic peptide [NT-proBNP]),
kidney function (estimated Glomerular Filtration Rate [eGFR]) and proteinuria (urine protein-creatinine ratio [PCR]
and albumin-creatinine ratio [ACR]). Outcomes were compared using paired t-test for each cross-over arm.
Results: BP-lowering benefits of a low-sodium intake (peripheral BP (mean ± SD) 148/82 ± 21/12 mmHg) from
high-sodium (159/87 ± 15/10 mmHg) intake were reflected in central BP and a reduction in eGFR, PCR, ACR,
NTproBNP and E/I ratio. There was no change in inflammatory markers, total or high molecular weight adiponectin.
Conclusions: Short-term benefits of sodium restriction on BP were reflected in significant change in kidney
function and fluid volume parameters. Larger, long-term adequately powered trials in CKD are necessary to confirm
these results.
Trial registration: Universal Trial Number U1111-1125-2149 registered on 13/10/2011; Australian New Zealand
Clinical Trials Registry Number ACTRN12611001097932 registered on 21/10/2011.
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Evidence for the benefits of sodium restriction beyond
blood pressure (BP) control has generated interest in the
CKD and general population literature. Observational
data from non-CKD populations indicates low sodium
intake is associated with reduced cardiovascular mortal-
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unless otherwise stated.reported benefits of sodium restriction independent of
BP, including reduced proteinuria [1,2] and arterial stiff-
ness [3].
Mechanisms driving these changes have yet to be elu-
cidated, however postulated drivers include metabolic
changes in systemic inflammation and fluid status [4-7].
Adipokines, including inflammatory makers, have been
shown to increase with high sodium diet in the general
population [8,9] however this has yet to be tested in kid-
ney disease. Fluid volume derangements occur with
sodium loading [10] and may heighten cardiovascular
risk through increasing left-ventricular hypertrophy [11].ral Ltd. This is an Open Access article distributed under the terms of the Creative
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a biomarker of the cardiac response to volume expan-
sion, is known to be elevated in patients with CKD, and
is reduced with a low sodium diet in CKD [12].
Our recent publication from the LowSALT CKD study
demonstrated a substantial effect of sodium on increas-
ing BP and proteinuria in Stage III and IV CKD [2]. This
current investigation is a post-hoc analysis aiming to
assess effects of dietary sodium restriction on kidney
function and metabolic markers (kidney function, fluid
volume, adipokines).
Methods
The LowSALT CKD study was a 6-week single-centre
double-blind randomized cross-over trial with two
2-week interventions. Methods for this study have been
described in detail previously [2,13]. Trial registration
numbers for the LowSALT CKD study are: Universal Trial
Number U1111-1125-2149, and Australian New Zealand
Clinical Trials Registry Number ACTRN12611001097932.
Participants
Briefly, the target population for the trial was adult
hypertensive (BP 130-169/≥70 mmHg), Stage III and IV
CKD (GFR 15–59 ml/min/1.73 m2) patients attending
a single tertiary nephrology service. Exclusion criteria
included salt-wasting CKD, pregnant or breastfeeding,
current prescription of medications providing >20 mmol
sodium per day, life expectancy <6 months, current in-
volvement in another intervention study, or insufficient
mental or physical capacity to adhere to the study proto-
col. Ethical approval was obtained through the Metro
South and University of Queensland Human Research
Ethics Committee. All participants gave fully informed
consent before participation in the study.
Study design
Participants were counseled by a single, trained dietitian
to follow a low sodium diet (aiming for a sodium intake
of 60–80 mmol/day) at the commencement of the study.
Following a 1-week run-in period, participants were ran-
domized to a high sodium diet (achieved via slow-
release sodium tablets providing an additional 120 mmol
sodium/day) or low sodium diet (placebo) with a 1-week
washout [2,13].
Outcome assessment
Peripheral (clinic) BP was measured by placing a cuff to
the brachial artery in the upper non-dominant arm at-
tached to an oscillometric semiautomatic sphygmoman-
ometer (Omron Healthcare Inc, Illinois, USA) after the
patient had been in the seated for at least 5 minutes,
taking an average of three consecutive measurements.
Central BP was assessed using radial applanation tono-metery to acquire an arterial pressure waveform, which
was then calculated using SphygmoCorTM CPV soft-
ware (AtCor Medical, Sydney, Australia) to give a central
BP estimation. The operator was blinded to baseline BP
results throughout the study.
Peripheral blood was drawn by venopuncture after an
overnight fast at each time point. Blood was collected
in Greiner Vacuette tubes with gel separator (serum -
#456071, lithium heparin plasma - #456083, Kremsmun-
ster, Austria). Blood was centrifuged within 30 minutes
after blood collection then serum and plasma were ali-
quoted into vials and stored at −80°C until analysis.
Analysis was performed in batches. Serum creatinine,
urate and C-reactive protein (CRP) were measured on
Beckman DxC800 general chemistry systems (Beckman
Coulter, Brea, CA, USA). In addition, the plasma marker
of fluid overload N-Terminal pro-Brain Natriuretic
Peptide (NTpro-BNP) was performed on the Roche
Elecsys e170 immunoassay system (Roche Diagnostics,
Mannheim, Germany).
A range of cytokines were measured. The inflamma-
tion markers, interleukin-6, tumor necrosis factor-α and
interferon-γ, were measured by an electrochemilumines-
cence technique using Human Pro-inflammatory Ultra-
sensitive Kit with the Sector Imager 6000 (Meso Scale
Discovery, Gaithersburg, Maryland, USA). The assay was
performed according to the manufacturer’s instructions
with CVs of 20% or less considered acceptable, as previ-
ously described [14]. Serum concentrations of total and
high molecular weight (HMW) and adiponectin were
measured in duplicate using ELISA (ALPCO Diagnos-
tics, Salem, NH, USA) according to the manufacturers’
instructions.
Kidney function was estimated using the CKD-EPI for-
mula for estimated Glomerular Filtration Rate (eGFR).
24-hour urine collections were undertaken using stand-
ard protocol and analyzed for albumin-creatinine (ACR)
and protein-creatinine ratio (PCR) (markers of kidney
damage) and total sodium content.
Fluid status was assessed by extracellular-to-intracellular
fluid ratio (E/I) and overhydration (in liters) measured
using the Body Composition Monitor (BCM) (Fresenius
Medical Care, Germany).
Investigators and participants were blinded to out-
come measurement throughout the study.Statistical analysis
Statistical analyses were performed using STATA (Ver-
sion 12) with significance set at p < 0.05.
Descriptive data are presented as mean and standard
deviation, or median and interquartile range if not nor-
mally distributed. Data that were non-normally distrib-
uted were transformed prior to analysis. Analysis was
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sodium intake.
To test for variation due to treatment order, analysis
of covariance was conducted with treatment type and
treatment order included in the model and observations




Participant characteristics and CONSORT diagram were
detailed in a previous publication [2]. Briefly, the sample
of 20 participants were mean ± SD age 69 ± 11 years,
with eGFR 32 ± 12 mL/min per 1.73 m2, 75% (n = 15/20)
male and 40% with diabetes (n = 9/20).
Effects of sodium restriction on outcomes
Table 1 demonstrates sodium excretion and BP as well
as kidney function, fluid status, and inflammatory
markers and adipokines. Peripheral systolic BP was re-
duced by mean 10 [95% CI 1–20] mm Hg from mean ±
SD 159 ± 14 mm Hg at the high sodium period to 148 ±
21 mm Hg at the low sodium period (p = 0.04), while
diastolic BP was reduced by 6 [95% CI 1–10] mm Hg
from 87 ± 10 mm Hg at the high sodium to 82 ± 12 mm
Hg at the low sodium period (p = 0.03). Central systolic
BP was reduced by 13 [95% CI 2 – 24] mm Hg fromTable 1 Results from a randomized-crossover trial of sodium
Baseline
Sodium excretion (mmol/24 hr)# 127 (80–1
Kidney function
eGFR# (mL/min) 32 (23–4
Serum creatinine# (μmol/L) 184 (135–2
Serum urate# (mmol/L) 0.44 (0.40–0
Protein: Creatinine (24 h urine)# (g/mol creat) 49 (12–9
Albumin: Creatinine (24 h urine)# (g/mol creat) 21 (2–65
Volume status
Extracellular/Intracellular fluid ratio 0.86 ± 0.1
Overhydration (L)# −0.6 (−1.6–
NT–proBNP (pg/mL)# NA
Inflammatory markers
C-reactive protein (mg/L)# 3.3 (1.6–5
Interleukin-6 (pg/mL)# NA
Interferon-gamma (pg/mL)# NA
Tumor necrosis factor – alpha (pg/mL)# NA
Total adiponectin (ng/L) 8.1 ± 3.5
High molecular weight adiponectin (μg/mL) 5.6 ± 3.1
Data are presented as mean ± standard deviation, median (interquartile range).
NA Data not avaliable.
*p < 0.05 High vs low sodium #log transformed prior to analysis.143 ± 20 mm Hg at the high sodium period to 130 ±
21 mm Hg at the low sodium period (p = 0.03) while
central diastolic BP was not significantly reduced (mean
change 4 [95% CI −2.2 – 10] mm Hg; from 84 ± 80 mm
Hg at the high sodium period to 80 ± 14 mm Hg at the
low sodium period; p = 0.20). Central pulse pressure was
significantly reduced by 9 [95% CI 2–17] mm Hg from
59 ± 16 mm Hg at the high sodium period to 50 ±
12 mm Hg at the low sodium period (p = 0.02).
Fluid markers were significantly reduced from the high
to the low sodium period (p < 0.05). However, inflamma-
tory markers and adipokines were not significantly dif-
ferent between the interventions (p > 0.05) (Table 1).
Effect of sodium restriction on outcomes did not vary
according to treatment order (p > 0.05).
Discussion
This study aimed to examine effects of sodium restric-
tion on central and peripheral BP, metabolic markers,
markers of kidney function, fluid volume and adipokines.
We found that a low sodium dietary intervention resulted
in significant reductions in both peripheral and central BP,
kidney function and fluid volume, but did not significantly
affect inflammatory markers or adiponectin.
Peripheral clinic BP was reduced by mean 10/6 mm Hg
from the high salt to the low salt period. This is compar-
able with ambulatory BP reduction of 10/4 mm Hg asrestriction in hypertensive CKD patients
High sodium Low sodium
87) 168 (146–219) 75 (58–112)*
2) 39 (23–39) 30 (17–36)*
44) 149 (135–230) 172 (157–276)*
.47) 0.39 (0.34–0.45) 0.46 (0.41–0.51)*
7) 68 (23–164) 41 (17–126)*
) 27 (5–127) 9 (2–82)*
4 0.92 ± 0.14 0.87 ± 0.13*
1.4) 0.8 (−1.1–2.6) −0.5 (−1.7–0.9)*
330 (167–793) 205 (124–528)*
.8) 2.8 (1.5–5.5) 2.7 (1.0–7.3)
1.9 (1.6–2.8) 1.9 (1.4–2.8)
0.8 (0.5–1.1) 1.0 (0.5–1.4)
6.8 (5.8–8.7) 7.3 (5.3–9.0)
7.8 ± 3.6 8.0 ± 3.7
3.9 ± 2.5 3.9 ± 2.6
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tory BP is considered to be more strongly related to car-
diovascular and renal risk than clinic BP [15,16],
reporting both measurements allows for greater com-
parability with studies using either of these measure-
ments alone.
Measurement of central BP has raised recent interest
due to its possibly stronger independent association with
cardiovascular events and chronic kidney disease com-
pared with peripheral BP [17]. Safar et al. (2002) mea-
sured central BP non-invasively in 180 haemodialysis
patients and found that a carotid pulse pressure increase
of 25 mm Hg increased the risk of all-cause mortality by
1.4 [95% CI 1.1-1.8] after adjusting for age, dialysis vin-
tage and previous cardiovascular events, while brachial
pulse pressure was not a significant predictor of mortal-
ity in this model [18]. We found that sodium restriction
reduced central systolic BP by 13 mm Hg and central
pulse pressure by 9 mm Hg. There is a paucity of data in
the pre-end stage CKD population examining clinical
outcomes based on this magnitude of change in central
BP. However, a recent non-CKD-specific meta-analysis
of 6 studies that measured central pulse pressure found
that a 10 mmHg increase of central pulse pressure in-
creased the age- and risk-factor-adjusted pooled relative
risk for cardiovascular events by 9% (RR 1.09, 95% CI
1.04–1.14) [19]. It is plausible that the reduction in cen-
tral BP found in this study would be of clinical benefit if
maintained long-term. Nevertheless, there is a need
for further research specifically in pre-end stage CKD
patients showing the effect of long-term central BP
changes on cardiovascular remodelling and events.
We also found a significant change in kidney function
parameters with a low sodium diet resulting in a de-
crease in eGFR mirrored by an increase in creatinine
and urate, compared with the high sodium diet. This is
consistent with findings from other studies investigating
the effect of sodium load on creatinine clearance show-
ing that a high sodium intake can result in increased
creatinine clearance, at least in the short term [20]. This
can be attributed to induced hyperfiltration associated
with increased intraglomerular pressure [21,22]. While
increasing GFR may be considered a reflection of im-
proved kidney function, inducing a state of hyperfiltra-
tion is associated with further kidney damage and
longer-term kidney function decline [23,24]. Similarly,
protein-to-creatinine and albumin-to-creatinine ratio
were both significantly reduced.
Recent controversy has been raised over the effects of
a sodium restricted diet on metabolic markers, with
findings in non-CKD populations, including recent ob-
servational trials in diabetes [25], citing activation of the
renin-angiotensin aldosterone system (RAAS) as a po-
tential negative consequence of low sodium intake.Clinical trials have shown that metabolic syndrome
modulates the response to dietary sodium intake [26]
and that sodium intake could affect plasma adiponectin
in healthy men, by modulation of the RAAS [9]. Inhib-
ition of RAAS through ACE-I and ARB therapy results
in increased adiponectin, and Liu et al. (2012) recently
indicated a high sodium diet resulted in higher adipo-
nectin levels due to suppression of RAAS [27]. Unlike
studies in the healhty popualtion [9,28]. In this present
study, adipokines were not impacted by sodium intake.
There appeared to be no change in inflammatory
markers, total or HMW adiponectin. It is possible that
our study was underpowered to detect a difference in
these markers, in addition to having a short intervention
period. There are also the potential confounding factors
to account for which are present in CKD, being a
chronic inflammatory condition, and resulting in re-
duced clearance of adipokines [29]. Finally, concurrent
treatment with RAAS blockade was prevalant in this co-
hort with 90% (n = 18/20) of participants in this study
were prescribed an ACE-I or alpha-receptor blocker. As
it is known that these medications increase adiponectin
together with suppression of RAAS [30]. This creates
additional challenges in the assessment of change in
these markers in this CKD population.
The hypothesis that higher sodium intake has pro-
inflammatory activity is physiologically plausible as sodium
loading results in tubulointerstitial endothelial inflamma-
tion in experimental studies (Dahl rats), independent of
haemodynamic changes [31]. Contrary to this, we did not
find a significant change in a broad range of cytokines
measured during the acute study, despite a significant
change in BP and proteinuria [2].
We found a significant change in fluid parameters
demonstrating deranged fluid status with a high sodium
diet. This volume change was reflected by NT-proBNP
increase in response to a high sodium diet. Correspon-
dingly, the high sodium diet resulted in increased
extracellular-to-intracellular fluid ratio, increased eGFR
and increased urine volume reflecting hyperfiltration
and natriuretic response as discussed earlier. The prog-
nostic impact of elevated NT pro-BNP in determining
BP and proteinuria response to RAAS blockade (ARB,
diuretic and sodium restriction) has been established by
Slagman et al. (2012) in proteinuric CKD patients [12].
In this study, NT pro-BNP was reduced by each therapy
of the RAAS blockade and dietary sodium restriction.
This group identified NT pro-BNP above the refer-
ence range of >125 ng/L predicted ‘salt sensitivity’ in
terms of both BP and proteinuria response. In our
sample, all except one participant had NT pro-BNP
levels exceeding 125 and these levels during the low
sodium period did not appear to correspond to BP or
proteinuria change.
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some of which, including small sample size and short
study duration, have previously been discussed [2]. Limi-
tations inherent in non-invasive measurement of central
BP were minimized by use of a single operator to reduce
observer error, and taking the measurements under con-
trolled circumstances. Some of the discrepancies highlighted
between our investigation and others may be due to the
range of comorbid factors including moderate-severe
CKD present in our population of hypertensive patients.
In addition, participants were maintained on their baselne
medication regimen throughout the investigation, which
may have impacted response to a number of outcomes, in-
cluding adipokine response. Research with longer follow-
up and larger sample size is needed to more confidently
elucidate the true effects of sodium restriction on kidney
function and metabolic markers.
Conclusions
The LowSALT CKD study is the first published double-
blind randomized controlled trial assessing the effect of
salt restriction on BP, central haemodynamics and in-
flammatory markers in CKD patients. We found that
two-weeks of sodium restriction produced statistically
and clinically significant reductions in peripheral and
central BP, as well as favourable changes in extracellular-
to-intracellular volume ratio, reflected by a change in
NT-pro-BNP. We found a considerable reduction in
eGFR with sodium restriction, potentially attributable to
resolution of hyperfiltration, although longer term re-
search is needed to confirm this. Sodium restriction did
not significantly change inflammatory markers in the
present study, although further research with a larger
sample size and longer followup is warranted. The
present study adds novel and valuable information re-
garding the pathogenesis of excessive sodium intake, and
benefits of sodium-restriction, in CKD patients.
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